Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?

@article{Silva2014CurrentMT,
  title={Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?},
  author={Jo{\~a}o S. Silva and Carlos Martins Silva and F. Jimenez Cruz},
  journal={Current Opinion in Urology},
  year={2014},
  volume={24},
  pages={21–28}
}
Purpose of review The pharmacological treatment of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH) is based on alpha-blockers and 5&agr;-reductase inhibitors isolated or in combination. Silodosin, an alpha-1A specific alpha-blocker is the only innovation in these groups of agents. This classical paradigm is being challenged by antimuscarinics, 5-phosphodiesterase inhibitors (PDE5i) and &bgr;3-adrenoreceptor agonists. Recent findings Silodosin is effective… 

Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015

The recent literature refines the knowledge on current therapeutic options and provides further evidence for an individualized, risk-adapted approach for male LUTS mainly depending on symptoms status, comorbidities and risk of disease progression.

Silodosin: A Review of Its Use in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia

Oral silodosin had a rapid onset of effect in men with lower urinary tract symptoms associated with BPH, with improvements seen in voiding and storage symptoms, maximum urinary flow rate and health-related quality of life in well-designed, 12-week trials.

Flurbiprofen alone and in combination with alfuzosin for the management of lower urinary tract symptoms

Addition of flurbiprofen increased the therapeutic effectiveness of alfuzosin by further improving symptoms in patients with LUTS/BPO and improved urine flow compared to baseline.

Emerging drugs for the treatment of benign prostatic hyperplasia

This review identifies potential and emerging medications for the treatment of Benign prostatic hyperplasia by searching the PharmaProjects database over the last 10 years, giving the reader an in-depth knowledge about the current pharmacological agents available and other potential treatments for BPH.

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.

A systematic review of randomised controlled trials comparing PDEIs versus placebo, ABs, or 5-ARIs for at least four weeks in men with BPH-LUTS found the combination of PDEI and AB may provide a small improvement in IPSS-total score.

Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia

It is indicated that doxazosin-GITS has significantly higher efficacy and lower AEs than tamsulosin in patients with lower urinary tract symptoms/benign prostate hyperplasia.

The promise of new urological procedures and medications to manage lower urinary tract symptoms related to benign prostatic obstruction.

The topic of procedure-based strategies to address symptomatic BPO is introduced through discussion of a controversial issue that all urologists will be familiar with: The question if and in whom an urodynamic evaluation is indicated prior to the surgical treatment of BPO.
...

References

SHOWING 1-10 OF 63 REFERENCES

Silodosin: a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia

The mechanism of action, uroselectivity and clinical efficacy/tolerability of Silodosin are discussed, and there is a higher risk of ejaculatory dysfunction, which may lead to discontinuation in younger men.

Silodosin in the treatment of benign prostatic hyperplasia

A critical review of the current literature on silodosin is offered, a novel alpha-blocker with unprecedented selectivity for α1A-adrenergic receptors, as compared with both α1B- and α1D -adrenoceptors, exceeding the selectivity of all currently used α1-blockers, and with clinically promising effects.

Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study

Evidence is provided that the combined therapy with terazosin plus tolterodine is a good approach for meeting the objectives of rapid, sustained, and safe improvements in the LUTS associated with BPH.

&agr;-Blockers for benign prostatic hyperplasia: the new era

Tamsulosin, alfuzosin slow release and silodosin do not require dose titration, and have all been shown to be effective in relieving LUTS/BPH independent of prostate size.
...